Connect your AI

Scholar Rock SRRK Stock Issuance Proceeds

Stock Issuance Proceeds at other companies

PTC TherapeuticsPTCT

$6.4M-59.3%

Travere Therapeutics, Inc.TVTX

$4.73M+11.5%

Cogent Biosciences, Inc.COGT

$5.76M+4,132%

BridgeBio PharmaBBIO

$22.59M—

Arrowhead ResearchARWR

$46.83M—

Roivant SciencesROIV

-$217.17M—

Other financials

Income statement

Revenue-—

Operating income-$102.0M-32.3%

Net income-$105.5M-41.2%

EPS (diluted)-$0.83-23.9%

Balance sheet

Cash & equivalents$430.5M+212%

Total debt$205.7M+226%

Total equity$276.0M-11.6%

Total assets$535.3M+31.3%

Cash flow

Operating cash flow-$82.1M-4.4%

CapEx$68.0K-74.9%

Free cash flow-$82.2M-4.1%

Valuation

Market cap$5.67B+85.5%

Enterprise value$5.45B+82.6%

P/S170.9×—

Profitability

Operating margin-231.8%—

Net margin-236.9%—

FCF margin-309.1%—

Returns & leverage

Return on equity-138.9%+60.1pp

Debt / equity0.7×+0.5×

Current ratio8.6×-1.6×

Where this comes from

Reported directly by Scholar Rock in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfCommonStock.

The official record: Scholar Rock’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Scholar Rock's stock issuance proceeds.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Scholar Rock's stock issuance proceeds?: Scholar Rock (SRRK) reported stock issuance proceeds of $98M in Q1 2026.
How has Scholar Rock's stock issuance proceeds changed year-over-year?: Scholar Rock's stock issuance proceeds increased by 1852.2% year-over-year, from $5.02M to $98M.
What is the long-term trend for Scholar Rock's stock issuance proceeds?: Over 3 years (2021 to 2025), Scholar Rock's stock issuance proceeds has grown at a 91.3% compound annual growth rate (CAGR), from $13.1M to $91.66M.
What does stock issuance proceeds mean?: Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.